ClinicalTrials.gg
CompletedNCT00365170Updated Dec 21, 2016

Efficacy and Safety of Insulin Aspart vs. Human Insulin During Pregnancy by Women With Type 1 Diabetes

A Phase 4 interventional study of human insulin and insulin aspart in Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 95 sites in 18 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-21.

Primary conditionDiabetes Mellitus, Type 1Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 1
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 1, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
419
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 — 1 open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 1.

Enrollment
6th of 35
419 · median 74
Started
2002
with 2 others
Phase 4
4 of 35
none open now
Registered
6th of 35
by date
Lead sponsor
10 of 35
Novo Nordisk A/S

Among the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, this one is the 6th largest by enrollment, is one of 3 that started in 2002, is one of 4 in phase 4, and was the 6th registered.

Diabetes Mellitus, Type 1

3,757 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

1 of the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Insulin, Regular, Human

Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

This trial was conducted in Europe, Middle East, North America and South America.

The aim of this trial was to compare the use of an intensified insulin treatment with insulin aspart (NovoRapid®) versus human insulin (Actrapid®) in pregnancy.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 1

Browse trials for

04

In context

Diabetes Mellitus, Type 1 Reclassified

3,757 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

This study's enrollment of 419 is above the median of 40 across 2,822 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 1 diabetes
  • Treated with insulin for at least 12 months
  • Either plan to become pregnant in the immediate future, willing to undertake pre pregnancy counselling, and has a screening lesser than or equal to 12.0%, or
  • Pregnant with normal singleton pregnancy, gestational age for at least 10 weeks at the time of randomisation, confirmed by ultrasound scan.

Exclusion criteria

Exclusion Criteria:

  • Previous birth of child with a major congenital malformation
  • More than 2 previous multiple miscarriages or stillbirths
  • Severe hyperemesis gravidarum, requiring hospitalisation, according to Investigator judgement
  • Subjects being treated for infertility
  • Proliferative retinopathy or maculopathy requiring acute treatment
  • Drug or alcohol abuse
  • Impaired renal, hepatic or cardiac function
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
419 participants (actual)

Interventions

07

What researchers measure

Primary outcomes

  1. Relative risk of major maternal hypoglycaemia

    Time frame: after 24 hours

Secondary outcomes

  1. Relative risk of major and minor hypoglycaemia

  2. Diabetic complications

  3. Obstetric complications

  4. Other Adverse Events

08

Study locations

95 sites
  • Novo Nordisk Investigational Site
    Ciudad de Buenos Aires, 1405, Argentina
  • Novo Nordisk Investigational Site
    Pcia de Cordoba, 5000, Argentina
  • Novo Nordisk Investigational Site
    Graz, 8036, Austria
  • Novo Nordisk Investigational Site
    Salzburg, 5020, Austria
  • Novo Nordisk Investigational Site
    Wien, 1090, Austria
  • Novo Nordisk Investigational Site
    Wien, A-1130, Austria
  • Novo Nordisk Investigational Site
    Sofia, 1431, Bulgaria
  • Novo Nordisk Investigational Site
    Halifax, Nova Scotia B3H 1V7, Canada
  • Novo Nordisk Investigational Site
    Ottawa, K1H 8L6, Canada
  • Novo Nordisk Investigational Site
    St John's, A1B 3V6, Canada
  • Novo Nordisk Investigational Site
    Toronto, M5G 1X5, Canada
  • Novo Nordisk Investigational Site
    Toronto, M5S 1B2, Canada
  • Novo Nordisk Investigational Site
    Vancouver, V5Z 1C6, Canada
  • Novo Nordisk Investigational Site
    Winnipeg, R3C 0N2, Canada
  • Novo Nordisk Investigational Site
    Zagreb, 10 000, Croatia
  • Novo Nordisk Investigational Site
    Hvidovre, 2650, Denmark
  • Novo Nordisk Investigational Site
    København ø, 2100, Denmark
  • Novo Nordisk Investigational Site
    Helsinki, 00029, Finland
  • Novo Nordisk Investigational Site
    Kuopio, 70210, Finland
  • Novo Nordisk Investigational Site
    Oulu, 90029, Finland
  • Novo Nordisk Investigational Site
    ANGERS cedex 09, 49033, France
  • Novo Nordisk Investigational Site
    Avignon, 84902, France
  • Novo Nordisk Investigational Site
    Bondy, 93143, France
  • Novo Nordisk Investigational Site
    Brest, 29609, France
  • Novo Nordisk Investigational Site
    Lille, 59037, France
  • Novo Nordisk Investigational Site
    MARSEILLE Cédex 05, 13385, France
  • Novo Nordisk Investigational Site
    Nantes, 44093, France
  • Novo Nordisk Investigational Site
    Nimes, 30006, France
  • Novo Nordisk Investigational Site
    Paris, 75181, France
  • Novo Nordisk Investigational Site
    PuyRicard, 13540, France
  • Novo Nordisk Investigational Site
    Strasbourg, 67000, France
  • Novo Nordisk Investigational Site
    Strasbourg, 67091, France
  • Novo Nordisk Investigational Site
    TOULOUSE cedex, 31054, France
  • Novo Nordisk Investigational Site
    Valenciennes, 59322, France
  • Novo Nordisk Investigational Site
    Berlin, 12051, Germany
  • Novo Nordisk Investigational Site
    Athens, 11521, Greece
  • Novo Nordisk Investigational Site
    Athens, 151 23, Greece
  • Novo Nordisk Investigational Site
    Athens, GR-11528, Greece
  • Novo Nordisk Investigational Site
    Dublin, DUBLIN 7, Ireland
  • Novo Nordisk Investigational Site
    Beer Sheva, 84101, Israel
  • Novo Nordisk Investigational Site
    Haifa, 31096, Israel
  • Novo Nordisk Investigational Site
    Jerusalem, 91031, Israel
  • Novo Nordisk Investigational Site
    Petah-Tikva, 49100, Israel
  • Novo Nordisk Investigational Site
    Apeldoorn, 7334 DZ, Netherlands
  • Novo Nordisk Investigational Site
    Brunssum, 6442 BE, Netherlands
  • Novo Nordisk Investigational Site
    Den Haag, 2597 AX, Netherlands
  • Novo Nordisk Investigational Site
    Eindhoven, 5631 BM, Netherlands
  • Novo Nordisk Investigational Site
    Roermond, 6043 CV, Netherlands
  • Novo Nordisk Investigational Site
    Rotterdam, 3045 PM, Netherlands
  • Novo Nordisk Investigational Site
    Utrecht, 3584 CX, Netherlands
  • Novo Nordisk Investigational Site
    Oslo, 0027, Norway
  • Novo Nordisk Investigational Site
    Tromsø, 9038, Norway
  • Novo Nordisk Investigational Site
    Trondheim, NO-7030, Norway
  • Novo Nordisk Investigational Site
    Krakow, 31-501, Poland
  • Novo Nordisk Investigational Site
    Lodz, 93-338, Poland
  • Novo Nordisk Investigational Site
    Lublin, 20-081, Poland
  • Novo Nordisk Investigational Site
    Olsztyn, 10-457, Poland
  • Novo Nordisk Investigational Site
    Poznan, 60-535, Poland
  • Novo Nordisk Investigational Site
    Szczecin, 71-455, Poland
  • Novo Nordisk Investigational Site
    Warszawa, 02-097, Poland
  • Novo Nordisk Investigational Site
    Wroclaw, 50-306, Poland
  • Novo Nordisk Investigational Site
    Moscow, 101000, Russian Federation
  • Novo Nordisk Investigational Site
    Moscow, 127411, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 199034, Russian Federation
  • Novo Nordisk Investigational Site
    Alicante, 03010, Spain
  • Novo Nordisk Investigational Site
    Girona, 17007, Spain
  • Novo Nordisk Investigational Site
    Santander, 39008, Spain
  • Novo Nordisk Investigational Site
    Sevilla, 41014, Spain
  • Novo Nordisk Investigational Site
    Ashington, NE63 9JJ, United Kingdom
  • Novo Nordisk Investigational Site
    Bath, BA1 3NG, United Kingdom
  • Novo Nordisk Investigational Site
    Belfast, BT12 6BA, United Kingdom
  • Novo Nordisk Investigational Site
    Birmingham, B9 5SS, United Kingdom
  • Novo Nordisk Investigational Site
    Bristol, BS10 5NB, United Kingdom
  • Novo Nordisk Investigational Site
    Cambridge, CB2 2QQ, United Kingdom
  • Novo Nordisk Investigational Site
    Edgbaston, Birmingham, B15 2TH, United Kingdom
  • Novo Nordisk Investigational Site
    Edinburgh, EH16 4SA, United Kingdom
  • Novo Nordisk Investigational Site
    Exeter, EX2 5AX, United Kingdom
  • Novo Nordisk Investigational Site
    Hull, HU3 2JZ, United Kingdom
  • Novo Nordisk Investigational Site
    Leeds, LS9 7TF, United Kingdom
  • Novo Nordisk Investigational Site
    Leicester, LE1 5WW, United Kingdom
  • Novo Nordisk Investigational Site
    Liverpool, L7 8XP, United Kingdom
  • Novo Nordisk Investigational Site
    London, SE5 9RS, United Kingdom
  • Novo Nordisk Investigational Site
    London, W12 OHS, United Kingdom
  • Novo Nordisk Investigational Site
    Newcastle, NE29 0LR, United Kingdom
  • Novo Nordisk Investigational Site
    Norfolk, NR4 7UY, United Kingdom
  • Novo Nordisk Investigational Site
    Northampton, NN1 5BD, United Kingdom
  • Novo Nordisk Investigational Site
    Nottingham, NG7 2UH, United Kingdom
  • Novo Nordisk Investigational Site
    Oxford, OX3 9DU, United Kingdom
  • Novo Nordisk Investigational Site
    Plymouth, PL8 8DQ, United Kingdom
  • Novo Nordisk Investigational Site
    Reading, RG51 5BS, United Kingdom
  • Novo Nordisk Investigational Site
    Sheffield, S10 2JF, United Kingdom
  • Novo Nordisk Investigational Site
    Sheffield, S5 7AU, United Kingdom
  • Novo Nordisk Investigational Site
    Southampton, SO16 6YD, United Kingdom
  • Novo Nordisk Investigational Site
    Stourbridge, DY3 3BG, United Kingdom
  • Novo Nordisk Investigational Site
    Worcester, WR5 1HN, United Kingdom
09

References and documents

Publications

  • Mathiesen ER, Kinsley B, Amiel SA, Heller S, McCance D, Duran S, Bellaire S, Raben A; Insulin Aspart Pregnancy Study Group. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care. 2007 Apr;30(4):771-6. doi: 10.2337/dc06-1887. PubMed 17392539 ↗
  • Hod M, Jovanovic L. Improving outcomes in pregnant women with type 1 diabetes. Diabetes Care. 2007 Jul;30(7):e62. doi: 10.2337/dc07-0488. No abstract available. PubMed 17596485 ↗
  • Hod M, Damm P, Kaaja R, Visser GH, Dunne F, Demidova I, Hansen AS, Mersebach H; Insulin Aspart Pregnancy Study Group. Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin in 322 subjects. Am J Obstet Gynecol. 2008 Feb;198(2):186.e1-7. doi: 10.1016/j.ajog.2007.08.005. Epub 2007 Oct 1. PubMed 17905178 ↗
  • McCance DR, Damm P, Mathiesen ER, Hod M, Kaaja R, Dunne F, Jensen LE, Mersebach H. Evaluation of insulin antibodies and placental transfer of insulin aspart in pregnant women with type 1 diabetes mellitus. Diabetologia. 2008 Nov;51(11):2141-3. doi: 10.1007/s00125-008-1120-y. Epub 2008 Aug 23. No abstract available. PubMed 18726086 ↗
  • Heller S, Damm P, Mersebach H, Skjoth TV, Kaaja R, Hod M, Duran-Garcia S, McCance D, Mathiesen ER. Hypoglycemia in type 1 diabetic pregnancy: role of preconception insulin aspart treatment in a randomized study. Diabetes Care. 2010 Mar;33(3):473-7. doi: 10.2337/dc09-1605. Epub 2009 Dec 10. PubMed 20007944 ↗
  • Damm P, Mersebach H, Rastam J, Kaaja R, Hod M, McCance DR, Mathiesen ER. Poor pregnancy outcome in women with type 1 diabetes is predicted by elevated HbA1c and spikes of high glucose values in the third trimester. J Matern Fetal Neonatal Med. 2014 Jan;27(2):149-54. doi: 10.3109/14767058.2013.806896. Epub 2013 Jun 20. PubMed 23687948 ↗
  • Altschuler JA, Casella SJ, MacKenzie TA, Curtis KM. The effect of cinnamon on A1C among adolescents with type 1 diabetes. Diabetes Care. 2007 Apr;30(4):813-6. doi: 10.2337/dc06-1871. PubMed 17392542 ↗
  • Williams MM, Clouse RE, Nix BD, Rubin EH, Sayuk GS, McGill JB, Gelenberg AJ, Ciechanowski PS, Hirsch IB, Lustman PJ. Efficacy of sertraline in prevention of depression recurrence in older versus younger adults with diabetes. Diabetes Care. 2007 Apr;30(4):801-6. doi: 10.2337/dc06-1825. PubMed 17392541 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2002, a primary completion of Apr 2005 and a completion of Apr 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2006
First posted
Aug 17, 2006
Start
Sep 2002
Primary completionActual
Apr 2005
CompletionActual
Apr 2005
Last update
Dec 21, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00365170
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Aug 17, 2006
Start date
Sep 2002
Primary completion
Apr 2005
Completion
Apr 2005
Last update
Dec 21, 2016

Study contacts

Global Clinical Registry (1452, GCR)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin, Regular, Human · Insulin Aspart

Start the discussion